A corporate venture arm invests across multiple funds, with each fund focused on a sector of strategic interest to the parent organization. The firm typically leads or co-leads rounds as a member of a syndicate of investors. The firm is actively seeking new investment opportunities across all funds.

The firm’s healthcare fund is looking for early stage companies working primarily within therapeutics. The firm seeks to invest in areas of strategic interest to its parent company including Immunology (Autoimmune), Oncology, Immuno-oncology, and Fertility. The firm generally looks for companies with novel first-in-class preclinical stage assets as well as novel platform technologies.

The firm is looking for privately held companies with experienced management teams able to take innovative solutions into commercially viable products. The firm looks to take an active role following investing taking a board seat, and is able to invest globally.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC fund based in the USA that was founded in 2016 invests in many sectors, including cloud based enterprise SaaS, Property Tech, and life sciences & healthcare. Within the life sciences, the firm is interested in therapeutics, medical device, digital health and healthcare IT companies. The firm generally invests in Series B and later rounds, and can invest anywhere from $1-20M in the initial check, and may participate in follow-on rounds. The firm is generally focused on investing in companies based in North America, but will consider global companies if they have a large presence in the US and are focused on the US market.

The firm will invest in therapeutics, medical device, digital health and healthcare IT companies. Within therapeutics, the firm is seeking companies in IND or later stages. In addition, the firm is interested in platform technologies, and will also invest in AI or machine learning based drug discovery companies. The firm will not invest in single asset or single modality companies. For medical devices, the firm primarily invests in 510K pathway devices that are FDA approved. The firm will not invest in DTC devices, and is less likely to consider de novo or PMA devices as well. Furthermore, the firm is most interested in devices that have a continuing source of revenue, such as a software application component. For digital health and healthcare IT companies, the firm is primarily focused on companies with B2B services, and will not invest in digital therapeutics. The firm is interested in companies that have greater than of $3M in ARR.

The firm is willing to lead or co-invest, but will generally take a board seat if they lead the investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A famiily office located in Canada looks to invest in clinical stage medical devices and diagnostics technologies as well as digital health companies. The firm looks to invest in companies with large market opportunities. The firm prefers to invest in Canadian companies, but will consider companies outside of Canada if they wish to expand to the Canadian market. The firm prefers to co-invest alongside other investors, and will invest $100,000-$250,000 in the initial investment, potentially contributing to additional rounds of funding.

The firm is looking for device companies, either in the medical device or diagnostic space. The firm will also consider digital health companies, focusing on mobile applications. For devices and diagnostics, the firm prefers 510k devices, but will consider PMA devices as well. These devices should be in the clinical development phase. The firm is indication agnostic, but does look for there to be a large market potential.

The firm looks for companies with strong management teams with good team dynamics, although previous entrepreneurial experience is not required.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large conglomerate headquartered in China’s primary business is in single-use medical devices with a wide range of product lines in consumables, orthopedic materials, and blood purification. The group also have subsidiaries in biopharmaceutical, healthcare services, finance, and real estate. As a leading provider of healthcare system solutions, the firm is actively expanding its healthcare business in China. The group is seeking product-based collaboration opportunities with early stage medical device businesses overseas, primarily through joint venture or incubation. The firm’s newly opened incubator serves as a one-stop shop for early stage medical device companies by providing capital, R&D services, clinical trial services, CFDA registration, and distribution channels. Typical investments range from RMB 1-30 million (US$0.1 – 4.4 M), while there is no set upper limit. The firm would also consider in-licensing opportunities.

The firm is focusing on medical devices with an elevated interest in coronary stent, vascular ultrasound, endoscope, and surgical devices. The firm is also interested in medical technologies that are complimentary to its product line, which includes: i) consumables (infusion sets, syringes, medical needles, blood bags, pre-filled syringes, blood sampling products, and other consumables); ii) orthopedic materials and iii) blood purification consumables and equipment. The group prefers products that have received FDA clearance/approval or at early commercial stage, while it is also open to projects that are pending an FDA decision. The group would also consider biopharmaceutical assets in kidney diseases.

The firm is seeking strong management teams with mature products that have received or are close to receiving regulatory approval. The firm is interested in forming joint venture or attracting overseas companies to its incubator.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The healthcare and life sciences branch of a large corporation  looks to invest primarily in Series A or later companies in digital health, medical devices, genomics and molecular diagnostics technologies, but can expand their focus conditionally. While some of their investments are strategic to the firm, the firm is willing to invest outside of corporate strategic areas. The firm is a global investor, and can act as both a strategic partner and a financial investor, depending on the company.

The firm can invest as a strategic manufacturing company, but is also interested in software-enabled technologies and connected devices. While the firm may consider PMA devices, most investments are in 510k-pathway products. For purely digital health products, such as IoT technology, the firm would like to see some revenue and market traction before investing. For both medical devices and digital health, the firm is agnostic to indication. The firm’s interest in genomics and molecular diagnostics primarily relate to the oncology space, and prefer to see technologies with some clinical data.

The firm may take a board seat after investing, if they are the lead or if they have strategic value to offer the portfolio company, but will generally not take a board seat if they are co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.co